Advertisement
The presentation entitled "Cell Therapy Devices and Concepts: AcellularMatrix Emulsion Injections to Induce Myofibroblast Proliferation andAngiogenesis" will take place on Monday, October 13th at 1:35 p.m. EDT in room145AB as part of the Innovative Devices and Futuristic Therapies Session.
Advertisement
"We are very proud to have Dr. Matheny included to present preclinicaldata from our next generation product within this prestigious panel,"commented Beecher Lewis, President and Chief Operating Officer of CorMatrixCardiovascular. "Our inclusion in this session reinforces the fact that ourtechnology continues to gain interest and acceptance among the cardiovascularcommunity."
About CorMatrix ECM Technology(TM)
CorMatrix Cardiovascular holds an exclusive license from Purdue Universityto research, develop, manufacture and market naturally occurring ECM productsfor cardiovascular applications. The company currently has U.S. clearance andEuropean approval with a CE Mark to market its ECM Technology as an implantfor pericardial closure, clearance in the U.S. for cardiac tissue repair, andis conducting preclinical studies on a number of cardiovascular applicationsincluding an emulsified, injectible form of its ECM Technology as a potentialtreatment for heart failure.
About CorMatrix Cardiovascular, Inc.
CorMatrix Cardiovascular, a privately held company based in Atlanta,Georgia, is dedicated to developing and delivering innovative biomaterialdevices that harness the body's own innate ability to regenerate damaged hearttissue. For more information visit http://www.cormatrix.com.
SOURCE CorMatrix Cardiovascular, Inc.
